Este estudio tiene como objetivo evaluar la farmacocinética (FC) y la seguridad de pembrolizumab SC formulado con berahialuronidasa alfa (MK-3475A) frente a pembrolizumab intravenoso (IV) (MK-3475), administrado con quimioterapia en el tratamiento de primera línea de participantes adultos con cáncer de pulmón de células no pequeñas metastásico. Las hipótesis primarias de este estudio son que pembrolizumab formulado con berahialuronidasa alfa subcutáneo (SC) es no inferior a pembrolizumab IV con respecto a los parámetros de FC.
Pembrolizumab (+) Berahyaluronidase alfa SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
Filgrastim will be administered as per the schedule specified for the arm.
Pegylated filgrastim will be administered as per the schedule specified for the arm.
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Mar del Plata, Buenos Aires, Argentina
Buenos Aires, Buenos Aires F.D., Argentina
Buenos Aires, Buenos Aires F.D., Argentina
Buenos Aires, Buenos Aires F.D., Argentina
Rosario, Santa Fe Province, Argentina
Córdoba, Argentina